Table 7.
Recent IA DDSs Reported in Preclinical and Clinical Trials
| Stage | Name | Formulation Type | Agent | Company |
|---|---|---|---|---|
| Approved | ZILRETTA | Polymeric microsphere | Triamcinolone acetonide | Flexion Therapeutics |
| TIVORBEX | Nanoparticle formulation | Indomethacin | iCeutica Inc. | |
| ZORVOLEX | Nanoparticle formulation | Diclofenac | iCeutica Inc. | |
| VIVLODEX | Nanoparticle formulation | Meloxicam | iCeutica Inc. | |
| Phase 3 | FX005 | Polymeric microsphere | p38 MAPK inhibitor | Flexion Therapeutics |
| FX006 | Polymeric microsphere | Glucocorticoid | Flexion Therapeutics | |
| Phase 2 | SB-061 | Polymeric formulation | Peptide | Symic Bio, Inc. |
| TLC-599 | Liposome formulation | Ropivacaine | Taiwan Liposome Co. | |
| SOLUMATRIX | Nanoparticle formulation | Naproxen | iCeutica Inc. | |
| Phase 1 | FX007 | Polymeric microsphere | TrkA receptor antagonist | Flexion Therapeutics |
| EP-104IAR | Polymeric microsphere | Fluticasone Propionate | Eupraxia Pharmaceuticals Inc. | |
| Pre-clinical | FX301 | Polymeric thermosensitive | Funapide | Flexion Therapeutics |
| OA GEL | Gel formulation | Diclofenac | PolyActiva Pty Ltd | |
| HA-based | Intra-articular formulation | Clodronate | Abiogen Pharma Sp |